Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/31677
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 17109/19415 (88%)
造访人次 : 2784081      在线人数 : 326
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻


    標題: Accuracy of a Staging System for Prognosis of 5-Year Survival of Patients With Nasopharyngeal Carcinoma Who Underwent Chemoradiotherapy
    作者: Huang, Chung-, I
    Chen, Li-Fu
    Chang, Shih-Lun
    Wu, Hung-Chang
    Ting, Wei-Chen
    Yang, Ching-Chieh
    貢獻者: Chi Mei Med Ctr, Dept Radiat Oncol
    E Da Canc Hosp, Dept Radiat Oncol
    Natl Yang Ming Univ Hosp, Dept Emergency Med
    Natl Yang Ming Univ, Sch Med
    Chi Mei Med Ctr, Dept Otolaryngol Head & Neck Surg
    Chi Mei Med Ctr, Dept Hematol & Oncol
    Natl Sun Yat Sen Univ, Inst Biomed Sci
    Chia Nan Univ Pharm & Sci, Dept Pharm
    關鍵字: Intensity-Modulated Radiotherapy
    Plus Adjuvant Chemotherapy
    Concurrent Chemoradiotherapy
    Locoregional Control
    Performance Status
    Scoring System
    Endemic Area
    7Th Edition
    日期: 2017-11
    上傳時間: 2018-11-30 15:52:32 (UTC+8)
    出版者: Amer Medical Assoc
    摘要: IMPORTANCE Concurrent chemoradiotherapy delivers a high level of tumor control and survival benefits for patients with nasopharyngeal carcinoma (NPC). However, many uncertainties still exist regarding the outcomes of chemoradiotherapy, making a more precise survival prognostic system necessary. OBJECTIVE To introduce a new staging system that combines tumor and clinical characteristics to improve the accuracy of prognosis for patients with NPC. DESIGN, SETTING, AND PARTICIPANTS This cohort study enrolled 207 patients with newly diagnosed NPC who underwent concurrent chemoradiotherapy between January 1, 2007, and December 31, 2014, at Chi-Mei Medical Center in Tainan, Taiwan. Data on these patients were collected from the cancer registry database of the Chi-Mei Medical Center. Patients who had a history of cancer or were unable to complete a full course of radiotherapy were excluded. Follow-up was completed on September 30, 2016, and the data analysis was performed from January 1, 2017, to February 28, 2017. MAIN OUTCOMES AND MEASURES The risk factors associated with 5-year disease-specific survival were incorporated into the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer TNM staging system to construct a new prognostic staging system. The chi(2) test for linear trend, the Akaike information criterion, and the C statistic were used to evaluate the monotonicity and discriminatory ability of the new prognostic staging system and the AJCC TNM staging system. RESULTS Of the 207 patients enrolled in the study, 157 (75.8%) were men, and the mean (SD) age was 48 (11) years. Multivariate analysis identified advanced clinical T stage (adjusted hazard ratio [aHR], 3.20; 95% CI, 1.58-6.48), poor performance status (aHR, 2.62; 95% CI, 1.30-5.28), and cumulative cisplatin dose lower than 100 mg/m(2) (aHR, 2.28; 95% CI, 1.10-4.74) as independent prognostic factors. The beta coefficients from the Cox proportional hazards regression model were used to develop an integer-based, weighted point system; advanced clinical T stage, poor performance, and cumulative cisplatin dose lower than 100 mg/m(2) were each assigned a score of 1. The sum of these risk scores was stratified into new stage I (score of 0), new stage II (score of 1), new stage III (score of 2), and new stage IV (score of 3). Compared with the AJCC TNM staging system, the new prognostic staging category had better monotonicity with a higher chi(2) value (17.8 vs 25.6) for linear trend, better discriminatory ability with a smaller Akaike information criterion (367 vs 360), and a greater C statistic (0.702 vs 0.740) for 5-year disease-specific survival. CONCLUSIONS AND RELEVANCE The new prognostic staging system has a better accuracy of prognosis of survival than the routinely used AJCC TNM staging system and thus is more useful in identifying high-risk patients for more intense treatment and care.
    显示于类别:[藥學系(所)] 期刊論文


    档案 描述 大小格式浏览次数

    在CNU IR中所有的数据项都受到原著作权保护.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈